Aarkstore - Epilepsy - Pipeline Review, H2 2014

Aarkstore Enterprise Aarkstore Enterprise

Description

“Epilepsy - Pipeline Review, H2 2014”, provides an overview of the Epilepsys therapeutic pipeline.
For more details : http://goo.gl/3U1CGu

Informations

• Publié par: Shubhangi
• Publié le: 21 avril 2015
• Nombre de lectures: 0
• Langue: English

Extrait

Aarkstore Enterprise


Aarkstore - Epilepsy - Pipeline Review, H2 2014
Browse Full Report
@
http://www.aarkstore.com/pharmaceuticals-healthcare/50610/Epilepsy-PipelineReview-H2-2014
Published: Aug 2014 | 247 Pages
PDF : $ 2000 | Site Licence: $ 4000 | Enterprise Wide Licence : $ 6000
Summary
“Epilepsy - Pipeline Review, H2 2014”, provides an overview of the Epilepsys therapeutic
pipeline.
This Market Research Report provides comprehensive information on the therapeutic
development for Epilepsy, complete with comparative analysis at various stages, therapeutics
assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases. It also reviews key players
involved in the therapeutic development for Epilepsy and special features on late-stage and
discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20
therapy areas and nearly 3,000 indications. The report is built using data and information sourced
from Global Markets Directs proprietary databases, Company/University websites, SEC filings,

Aarkstore Enterprise

investor presentations and featured press releases from company/university sites and
industryspecific third party sources, put together by Global Markets Directs team. Drug profiles/records
featured in the report undergoes periodic updation following a stringent set of processes that ensures
that all the profiles are updated with the latest set of information. Additionally, including
live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to
gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and
relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Epilepsy
- The reviews key pipeline products under drug profile section which includes, product
description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Epilepsy and enlists all
their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Epilepsy products under development by companies and universities/research
institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till
discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epilepsy pipeline on the basis of target, MoA, route of administration and molecule
type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate
effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective
counterstrategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for
Epilepsy

Aarkstore Enterprise

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus
of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors
that drove them from pipeline
Order full Report with TOC and Sample page
visit:
http://www.aarkstore.com/pharmaceuticals-healthcare/50610/Epilepsy-Pipeline-ReviewH2-2014
Table of Contents:
Introduction 8
Global Markets Direct Report Coverage 8
Epilepsy Overview 9
Therapeutics Development 10
Pipeline Products for Epilepsy - Overview 10 for - Comparative Analysis 11
Epilepsy - Therapeutics under Development by Companies 12 - Investigation by Universities/Institutes 17
Epilepsy - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage 20
Early Stage Products 21
Epilepsy - under Development by Companies 22 - Products Investigation by Universities/Institutes 26
Epilepsy - Companies Involved in Therapeutics Development 27
Allergan, Inc. 27
Neurocrine Biosciences, Inc. 28
Novartis AG 29
Acorda Therapeutics, Inc. 30
Astellas Pharma Inc. 31
Chong Kun Dang Pharmaceutical Corp. 32
Eisai Co., Ltd. 33
List Of Tables
Number of Products under Development for Epilepsy, H2 2014 17 of for Epilepsy - Comparative Analysis, H2 2014 18

Aarkstore Enterprise

Number of Products under Development by Companies, H2 2014 20 of by H2 2014 (Contd..1) 21
Number of Products under by Companies, H2 2014 (Contd..2) 22 of Development by H2 2014 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2014 25
Comparative Analysis by Late Stage Development, H2 2014 26 by Clinical Stage H2 2014 27 Analysis by Early Stage H2 2014 28
List Of Figures
Number of Products under Development for Epilepsy, H2 2014 17 of for Epilepsy - Comparative Analysis, H2 2014 18
Number of Products under by Companies, H2 2014 19 of Investigation by Universities/Institutes, H2 2014 24
Comparative Analysis by Late Stage Development, H2 2014 26 by Clinical Stage H2 2014 27 Analysis by Early Stage Products, H2 2014 28
Assessment by Monotherapy Products, H2 2014 75
Number of Products by Top 10 Target, H2 2014 76 of by Stage and Top 10 Target, H2 2014 77
Related Market Research reports:
 Blirt S.A. - Product Pipeline Review - 2014
 Auris Medical Holding AG - Product Pipeline Review - 2014
 Integral Molecular, Inc. - - 2014
 DaVinci Biosciences, LLC - Product Pipeline Review - 2014
 Actavis plc - Product Pipeline Review - 2014
 TiGenix NV - - 2014
 Egenix, Inc. - Product Pipeline Review - 2014
 SkyePharma PLC - Product Pipeline Review - 2014
 MediWound Ltd. - - 2014
 BioTech Tools s.a. - Product Pipeline Review - 2014
About Aarkstore Enterprise

Aarkstore Enterprise
Enterprise is a leading provider of business and financial information and solutions worldwide. We
specialize in providing online market business information on market research reports, books, magazines,
conference at competitive prices, and strive to provide excellent and innovative service to our customers.
Contact Details:
Aarkstore Enterprise
Phone: [phone]
Email: [e-mail]
Our Website: http://www.aarkstore.com
Our Blog : http://www.aarkstore.com/blog/
Latest News : http://www.aarkstore.com/news
Facebook: https://www.facebook.com/aarkstoredotcom